Updates in Diagnosis, Management, and Treatment of Neuroblastoma
Clinical trials for regimens designed to target individual genetic aberrations in tumors are underway, potentially improving outcomes for high‑risk neuroblastoma patients.
Neuroblastoma presents with highly variable outcomes, from >90% survival in low‑risk disease to <50% in high‑risk cases. Recent advances in biology have improved risk stratification and reduced treatment intensity for many patients. Yet, high‑risk and relapsed neuroblastoma remain challenging, necessitating newer therapeutic approaches. This review covers epidemiology, diagnosis, risk stratification, and recent advances in treatment for both newly diagnosed and relapsed cases, highlighting the promise of novel tumor targets and cell‑mediated immunotherapy agents. Ongoing clinical trials are testing regimens tailored to individual genetic aberrations, suggesting that combination therapies may be essential for improved survival and cure.
Improving therapeutic strategies for high‑risk neuroblastoma could increase survival and cure rates, addressing a critical unmet need in pediatric oncology.
Bizonyítékszint: Korai humán adat. Kis vagy feltáró emberi adat.
Kapcsolódó jelek
- Targeted immunotherapies for anaplastic lymphoma kinase-positive pediatric tumors: current advances and future perspectives
- Coexpression of MYCN and ALK Induces Neuroblastoma-Like Tumors From Human iPS Cell-Derived Cranial Neural Crest Cells.
- Emerging clinical and research approaches in targeted therapies for high-risk neuroblastoma
- Frequency and Clinical Significance of Clonal and Subclonal Driver Mutations in High‑Risk Neuroblastoma at Diagnosis: A Children's Oncology Group Study
- Treatment and Survival of Childhood Neuroblastoma: Evidence from a Population-Based Study in the United States